• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia launches new AI platform

AIFORIAAnalyst Comment18.12.2025 klo 09.25
Antti Luiro, Frans-Mikael Rostedt
Discuss

Translation: Original published in Finnish on 12/18/2025 at 8:20 am EET.

Aiforia announced on Wednesday the launch of a new generation AI platform that utilizes Vision Transformer technology. The new technology promises to accelerate the development of AI models and improve their performance, supporting the expansion of the company's product portfolio. The news has no direct impact on our forecasts, but we view the increased efficiency in product development positively, as it partly mitigates risks related to the company's innovation capabilities after cost cuts and supports its long-term competitiveness.

The new Foundation Engine solution enhances model development

Aiforia announced on Wednesday that it is expanding its AI platform with a new solution called Foundation Engine, which is based on the Vision Transformer architecture. According to the company, the new solution combines so-called foundation models, pre-trained on extensive image datasets, with task-specific annotations made by pathologists. Aiforia highlights that the key benefits of the technology are the acceleration of AI model development and the improved generalizability of models to different image datasets. The new technology will be deployed in Aiforia's own product development and will also be integrated into the Aiforia Create development tool available to customers.

The company referred to the benefits of the expansion in its own product development earlier in the fall, so the launch does not come as a particular surprise or put pressure on forecast changes. In any case, the acceleration of model development supports the company's goals to improve its operational efficiency. Aiforia has recently focused on optimizing its cost structure and securing its path to profitability. In our view, more efficient product development through new technology mitigates the risks of cost savings to the company's innovation pace and supports the company's ability to maintain competitiveness in the long term. In addition to supporting the expansion of the product portfolio in the clinical segment, which is central to Aiforia's growth strategy, the technology also fundamentally strengthens Aiforia's product for its research customers who develop their own models on the Aiforia platform.

 

Login required

This content is only available for logged in users

Create account

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures19.11.2025

202425e26e
Revenue2.93.35.1
growth-%18.9 %16.4 %55.0 %
EBIT (adj.)-12.2-10.9-8.6
EBIT-% (adj.)-427.8 %-328.4 %-167.6 %
EPS (adj.)-0.41-0.39-0.28
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

In my opinion, the financing news was much better than I expected. I was certainly expecting a directed share issue, which would have been frustrating...
6/17/2026, 7:21 AM
by JusaVaan
23
nuways-ag.com NuWays Platform
6/17/2026, 6:28 AM
by Salvelinus
10
ecdp2026.org European Society of Digital and Integrative Pathology | ECDP2026 | 22nd... Today marks the start of a congress where Aiforia is...
6/17/2026, 5:44 AM
by Salvelinus
16
These types of bridge financing arrangements are quite common nowadays. It also indicates that the company genuinely believes cash flow positivity...
6/16/2026, 4:01 PM
24
Usually a company can and should raise debt only when the stock and cash flows are strong enough, this is kind of the opposite situation
6/16/2026, 1:53 PM
by Bullbear
1
Yeah, even if the loan eliminates the acute financing risk, we will likely see at least one more share issue. It is also possible that the potential...
6/16/2026, 9:49 AM
6
Below are the analyst’s comments. Referring to management’s previous statements, this is bridge financing instead of share issues for the period...
6/16/2026, 6:11 AM
by Opa
25